亚宝药业
(600351)
| 流通市值：46.30亿 | | | 总市值：46.30亿 |
| 流通股本：7.20亿 | | | 总股本：7.20亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 771,213,413.14 | 2,909,765,256.74 | 2,199,444,283.52 | 1,532,836,354.03 |
| 营业收入 | 771,213,413.14 | 2,909,765,256.74 | 2,199,444,283.52 | 1,532,836,354.03 |
| 二、营业总成本 | 644,615,339.06 | 2,620,740,517.25 | 1,974,246,824.7 | 1,346,518,840.4 |
| 营业成本 | 336,338,751.8 | 1,226,341,851.74 | 948,861,867.37 | 655,433,994.32 |
| 税金及附加 | 10,057,933.64 | 35,285,959.29 | 27,761,003.46 | 19,276,510.32 |
| 销售费用 | 200,638,292.84 | 971,690,618.15 | 710,757,402.62 | 485,792,926.58 |
| 管理费用 | 66,748,757.12 | 265,909,082.3 | 198,578,606.48 | 130,668,672.99 |
| 研发费用 | 31,012,841.2 | 118,289,869.23 | 84,570,401.25 | 51,797,296.07 |
| 财务费用 | -181,237.54 | 3,223,136.54 | 3,717,543.52 | 3,549,440.12 |
| 其中:利息费用 | 1,834,594.18 | 12,298,232.82 | 10,734,565.73 | 8,368,139.67 |
| 其中:利息收入 | 2,059,471.68 | 9,486,872.16 | 7,303,322.34 | 4,986,581.07 |
| 加:公允价值变动收益 | -6,744.61 | -2,582,034.12 | -2,233.84 | -107,043.65 |
| 加:投资收益 | 223,745.26 | -2,763,516.28 | -2,122,131.65 | -1,542,194.25 |
| 资产处置收益 | 44.28 | 1,121,960.35 | 970,334.22 | 946,183.39 |
| 资产减值损失(新) | -235,384.3 | -93,749,254.15 | -1,089,498.72 | -1,364,192.53 |
| 信用减值损失(新) | -835,836.03 | 2,071,445.77 | 1,790,997.36 | -4,351,769.33 |
| 其他收益 | 11,194,349.24 | 33,211,691.29 | 20,549,304.35 | 11,845,473.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 136,938,247.92 | 226,335,032.35 | 245,294,230.54 | 191,743,970.42 |
| 加:营业外收入 | 570,042.61 | 2,954,284.62 | 1,157,393.61 | 635,693.94 |
| 减:营业外支出 | 120,924.26 | 10,308,094.32 | 1,636,929.93 | 895,891.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 137,387,366.27 | 218,981,222.65 | 244,814,694.22 | 191,483,772.42 |
| 减:所得税费用 | 27,615,361.72 | 39,067,537.42 | 32,313,149.84 | 24,891,439.23 |
| 六、净利润 | 109,772,004.55 | 179,913,685.23 | 212,501,544.38 | 166,592,333.19 |
| 持续经营净利润 | 109,772,004.55 | 179,913,685.23 | 212,501,544.38 | 166,592,333.19 |
| 归属于母公司股东的净利润 | 112,264,323.74 | 199,585,789.8 | 213,815,982.55 | 168,027,465.72 |
| 少数股东损益 | -2,492,319.19 | -19,672,104.57 | -1,314,438.17 | -1,435,132.53 |
| (一)基本每股收益 | 0.15 | 0.26 | 0.28 | 0.22 |
| (二)稀释每股收益 | 0.15 | - | 0.28 | 0.22 |
| 八、其他综合收益 | - | -4,402,698.14 | -97,307.43 | -3,901.19 |
| 归属于母公司股东的其他综合收益 | - | -4,402,698.14 | -97,307.43 | -3,901.19 |
| 九、综合收益总额 | 109,772,004.55 | 175,510,987.09 | 212,404,236.95 | 166,588,432 |
| 归属于母公司股东的综合收益总额 | 112,264,323.74 | 195,183,091.66 | 213,718,675.12 | 168,023,564.53 |
| 归属于少数股东的综合收益总额 | -2,492,319.19 | -19,672,104.57 | -1,314,438.17 | -1,435,132.53 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |